{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(6)"],"submitter":["Agren UM"],"pubmed_abstract":["<h4>Objectives</h4>To compare the effects of two monophasic combined oral contraceptives, containing either nomegestrol acetate/17β-oestradiol (NOMAC/E2) or levonorgestrel/ ethinylestradiol (LNG/EE) on endocrine function, androgens, and sex hormone-binding globulin (SHBG).<h4>Methods</h4>Randomised, open-label, multi-centre trial involving 121 healthy women, aged 18-50 years old. Participants received NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60) or LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61) for six cycles. The primary outcome was the change from baseline to cycle 6 in markers of adrenal and thyroid function, androgens, and SHBG.<h4>Results</h4>Total cortisol, corticosteroid-binding globulin (CBG), and thyroxine-binding globulin (TBG) increased from baseline in both groups,"],"journal":["The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception"],"pagination":["458-67"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3233273"],"repository":["biostudies-literature"],"pubmed_title":["Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function."],"pmcid":["PMC3233273"],"pubmed_authors":["Rantala ML","Rautiainen H","Agren UM","Sommer WF","Maenpaa-Liukko K","Mommers E","Anttila M"],"additional_accession":[]},"is_claimable":false,"name":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.","description":"<h4>Objectives</h4>To compare the effects of two monophasic combined oral contraceptives, containing either nomegestrol acetate/17β-oestradiol (NOMAC/E2) or levonorgestrel/ ethinylestradiol (LNG/EE) on endocrine function, androgens, and sex hormone-binding globulin (SHBG).<h4>Methods</h4>Randomised, open-label, multi-centre trial involving 121 healthy women, aged 18-50 years old. Participants received NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60) or LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61) for six cycles. The primary outcome was the change from baseline to cycle 6 in markers of adrenal and thyroid function, androgens, and SHBG.<h4>Results</h4>Total cortisol, corticosteroid-binding globulin (CBG), and thyroxine-binding globulin (TBG) increased from baseline in both groups,","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Dec","modification":"2025-04-05T13:50:39.959Z","creation":"2019-03-27T00:46:49Z"},"accession":"S-EPMC3233273","cross_references":{"pubmed":["21942708"],"doi":["10.3109/13625187.2011.614363"]}}